ClinicalTrials.gg
RecruitingNCT07249632Updated Apr 9, 2026

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

A Phase 3 interventional study of Telitacicept and Placebo in Myasthenia Gravis, Ocular, sponsored by RemeGen Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Planned enrollment
15th of 67
120 · median 40
Started
2026
with 17 others
Phase 3
24 of 88
7 open now
Primary completion
2026-12
later than 20 of 59 live
Registered
70th of 88
by date
Lead sponsor
3 of 88
RemeGen Co., Ltd.

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 15th largest by planned enrollment of the 67 interventional ones that give a count, is one of 18 that started in 2026, is one of 24 in phase 3, reaches primary completion later than 20 of the 59 other live ones, and was the 70th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America [MGFA] Clinical Classification Type I) will be randomized in a 1:1 ratio to receive either Telitacicept or a matching placebo. Subjects must be on a stable standard-of-care therapy and have an MG Impairment Index (PRO) ocular score of ≥6 at screening and baseline.The dose is age and weight based.The primary objective is to evaluate the efficacy of Telitacicept compared to placebo in treating OMG.The primary efficacy endpoint is the change from baseline in the MGII (PRO) ocular score at Week 24. Secondary endpoints include changes from baseline in other ocular and total scores from MGII, Myasthenia Gravis-Activities of Daily Living (MG-ADL), MG Clinical Absolute Score, and the 15-item Myasthenia Gravis Quality of Life Revised scale (MG-QOL15r). Safety and tolerability will be monitored throughout the study.

Read the detailed description

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of Telitacicept in subjects with Ocular Myasthenia Gravis (OMG). The study will be conducted at multiple centers.

Eligible subjects will be randomized in a 1:1 ratio to one of two treatment arms:

Arm 1: Telitacicept Arm 2: Placebo Randomization will be stratified by two factors: Acetylcholine Receptor (AChR) antibody status (positive vs. negative) and age (\<18 years vs. ≥18 years).

Primary Objective:

To evaluate the efficacy of Telitacicept compared to placebo in the treatment of subjects with Ocular Myasthenia Gravis.

Primary Endpoint:

Change from baseline in the Myasthenia Gravis Impairment Index (Patient-Reported Outcomes) [MGII (PRO)] ocular score at Week 24.

Study Population:

A total of approximately 120 subjects will be enrolled.

Intervention:

Subjects will receive either Telitacicept or a matching placebo. The dose will be determined based on the subject's age and body weight at baseline.

The placebo will be identical in appearance to Telitacicept to maintain the blind.

Safety Assessments:

Safety and tolerability will be assessed through the monitoring and recording of adverse events (AEs), serious adverse events (SAEs), vital signs, physical examinations, and regular laboratory tests (hematology, serum chemistry, urinalysis). An independent Data Monitoring Committee (DMC) will be established to monitor the safety of the trial.

03

Conditions studied

  • Myasthenia Gravis, Ocular

Browse trials for

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed the form.
  2. Age 12 to 80 years, inclusive, male or female.
  3. Body weight ≥30 kg.
  4. Diagnosis of Myasthenia Gravis (MG) with documented clinical features consistent with the disease.
  5. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Type I.
  6. On a stable standard-of-care (SOC) treatment regimen.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diseases requiring systemic therapy.
  2. laboratory abnormalities.
  3. Use of other (not part of the stable SOC) within 1 month prior to randomization.
  4. Presence of an acute or chronic infection requiring treatment.
  5. Current active hepatitis or history of severe liver disease.
  6. Positive for antibodies.
  7. Positive for syphilis antibodies (non-specific or specific).
  8. Poorly controlled diabetes mellitus, defined as >9.0% or fasting blood glucose ≥11.1 mmol/L.
  9. Subjects with thymoma (classified as ≤ Stage II for benign and ≥ Stage III for malignant according to the Masaoka staging system) .
  10. Presence of uncontrolled chronic degenerative diseases, psychiatric disorders, or neurological diseases other than MG that could interfere with study assessments.
  11. Other diseases causing ptosis, peripheral muscle weakness, or diplopia (e.g., Graves' ophthalmopathy, blepharospasm, progressive external ophthalmoplegia, muscular dystrophy, brainstem or cranial nerve lesions, etc.).
  12. Known allergy to human-derived biological products.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Telitacicept

    Drug: Telitacicept

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • The dosage is administered based on the subject's age and baseline body weight.

  • DrugPlacebo

    The placebo contains no active ingredients. To maintain the blind, the placebo matches the active drug in all physical aspects.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the MGII (PRO) ocular score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Change from baseline in the MGII (PRO + PE) ocular score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Change from baseline in the MG-ADL ocular score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Change from baseline in the MG Clinical Absolute Score ocular score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Change from baseline in the total MGII score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  5. Change from baseline in the total MG-ADL score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  6. Change from baseline in the MG-QOL15r total score

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  7. Incidence and severity of adverse events

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: From signing of informed consent until 4 weeks after the last dose.

Other outcomes

  1. Number and proportion of subjects who achieve MSE, defined as an MG-ADL total score of 0 or 1

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Number and proportion of subjects in each MGFA-PIS category

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Number and proportion of subjects in each PGI-S and PGI-C category

    at Week 24

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 11 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Jan 13, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 28, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07249632
Lead sponsor
RemeGen Co., Ltd.
Collaborators
Huashan Hospital, Beijing Hospital
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Jan 13, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Apr 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion